Does TRICARE Cover Zepbound? Prior Authorization, Formulary Tier, and Appeal Steps

Check Eligibility Before Starting the Coverage Request

TRICARE's current weight-loss coverage page lists Prime and Select plans and their eligible variants, including Reserve Select, Retired Reserve and Young Adult options. The treatment must be medically appropriate, prescribed through the required network-provider route and authorized. A clinician's prescription is only one part of that decision. [1]

Express Scripts identifies Zepbound among the weight-loss medications available to eligible Prime and Select beneficiaries with approved prior authorization. Use its formulary search for the exact pen, vial or other presentation. The result for one formulation does not establish coverage for every product containing tirzepatide. [2,3]

What the Current Prior-Authorization Form Actually Asks

The form linked from the Zepbound pen formulary result is dated September 9, 2026. It covers Wegovy products and Zepbound Pen Injector, with different branches for age, indication, initial treatment and renewal. Your prescriber should use the relevant branch rather than transferring another drug's criteria. [4]

For the adult initial weight-management pathway, the form asks about:

• Provider and plan: An MTF or TRICARE network provider who assessed the patient and developed the treatment plan, and enrollment in Prime or Select.
• BMI and conditions: The form separates BMI below 27, BMI 27 to 29 with a relevant comorbidity, and higher BMI categories. The clinician documents the actual measurements and diagnosis.
• Lifestyle treatment: At least six months of behavioral modification and dietary restriction without the desired weight loss, with continued participation and documentation in the medical record.
• Previous medication or exceptions: The specific treatment questions described below.
• Clinical eligibility: The prescriber completes the form's remaining assessment, including the existing thyroid-cancer/MEN2 eligibility question. [4]

The form states that initial approval lasts 12 months and requires annual renewal. The renewal branch asks about continued lifestyle treatment and documented response. For adults receiving weight-management treatment, it asks whether at least 5% of baseline weight has been lost after full dose titration. An interruption and restart follows the form's initial-treatment pathway; that administrative instruction is not a medication restart schedule. [4]

Step Therapy: Use the Named Drugs and Exception Branches

The current adult weight-management form asks about three months of generic phentermine, benzphetamine, diethylpropion or phendimetrazine, and whether baseline weight fell by 5%. It also provides branches for contraindications, an adverse reaction not expected with the requested medication, or a response that still leaves substantial residual weight-management needs. [4]

It does not list a universal 90-day trial of metformin, Wegovy or Qsymia as the sequence described on this page. A previous prescription alone does not prove that the current requirements have been met. The prescriber should document the actual drug, dates, duration, response and relevant exception through the form. These are coverage criteria, not instructions to start another drug without a prescribing decision. [4]

Formulary Results and the Price of the Actual Fill

On October 5, 2026, the public formulary tool's illustrative result for a 40-year-old male and Zepbound 5 mg/0.5 mL Pen Injector showed coverage with limitations. It displayed $0 for active-duty fills through the listed covered channels, and non-active-duty prices of $48 at retail and $44 through home delivery. [3]

Those figures are a dated example, not a personal quote. The medication-specific coverage guide limits retail to 30 days and, if available, home delivery or MTF supply to 60 days, even though the general home-delivery price card says up to 90 days. Confirm the quantity actually authorized and dispensed. The guide also says retail prices can vary with the product's NDC. [3]

TRICARE's pharmacy-cost page separates beneficiary groups, formulary categories and pharmacy channels. Covered MTF dispensing can be $0, but that does not establish local stock or procurement timing. The same page treats non-covered drugs differently from drugs covered with authorization. Ask the pharmacy to price the actual covered prescription instead of estimating from a supposed universal specialty tier. [5]

TRICARE For Life and Medicare Are Different Coverage Questions

TRICARE explicitly excludes weight-loss drug coverage for TRICARE For Life. A prior authorization does not turn that excluded benefit into Prime or Select coverage. [1,6]

Medicare's GLP-1 Bridge began July 1, 2026 for eligible people with qualifying Part D coverage. Its Zepbound benefit is specifically for KwikPen, not the single-dose pen or vial. Eligibility, clinical criteria and authorization belong to that separate program. Medicare lists a $50 monthly copayment; this does not establish that TFL pays the residual amount or automatically coordinates the prescription. [7]

If you have Medicare, ask which program is processing the actual formulation and indication. A statement about a weight-management benefit should not be substituted for coverage of another indication. [6,7]

Appealing a Pharmacy Decision

TRICARE directs pharmacy appeals to Express Scripts when a pharmacy claim, medical-necessity request or prior authorization is denied. Its current instructions specify a letter postmarked within 90 days of the decision. Include the decision, explain why you disagree and provide supporting documentation. If some records are still pending, send what is available and identify what will follow. [8]

If Express Scripts denies the appeal, follow that letter's instructions for a second-level appeal. The regional medical-benefit and ECHO routes are not a substitute for the published pharmacy process. The reason for denial matters: missing evidence, an unmet drug criterion and enrollment in a plan without the benefit require different responses. No appeal success rate or fixed decision timeline is established here. [8]

Savings Programs and Expected Timing

Lilly's commercial Zepbound savings program excludes people enrolled in TRICARE and other listed government-funded programs. Its separately described self-pay programs have their own formulation and payment terms. Do not apply a commercial-insurance savings price to a TRICARE pharmacy claim, or assume every manufacturer program has identical eligibility. [9]

For timing, ask whether the prescriber has submitted the correct form, whether more information is needed, whether authorization has been issued and whether the actual pharmacy has the covered product. The sources reviewed here do not establish a universal 5-to-10-business-day approval or a guaranteed first-injection week.

What Trial Results Can Contribute

SURMOUNT-1 randomized 2,539 adults with obesity or overweight and a weight-related condition, without diabetes, to tirzepatide or placebo with lifestyle intervention. At 72 weeks, mean weight change was -15.0%, -19.5% and -20.9% for the 5, 10 and 15 mg groups, versus -3.1% for placebo. At least 20% weight loss occurred in 57% of the 15 mg group, not 63%. [10]

These are trial results, not a promised individual outcome or an authorization criterion. STEP 1 studied semaglutide in a separate population and trial; comparing their averages does not create a head-to-head result or prove a TRICARE exception. [10,11]